Core Insights - Aclarion, Inc. is expanding the access of its Nociscan technology across multiple sites in New York and New Jersey to address the growing demand for chronic low back pain solutions [1][2] - The expansion is supported by enhanced remote operations capabilities and increased availability of Magnetic Resonance Spectroscopy (MRS) within RadNet [1][2] Company Overview - Aclarion is a healthcare technology company that utilizes biomarkers and proprietary AI algorithms to assist physicians in identifying chronic low back pain locations [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][5] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge [4] - The Nociscan solution quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][5] Strategic Partnerships - Lenox Hill Radiology operates 79 locations in New York and has adopted Nociscan to enhance access for leading spine physicians [2][3] - New Jersey Imaging Network, with 33 locations, was the first in NJ to adopt Nociscan, facilitating support for local and out-of-market referrals [3]

Core Insights - Aclarion, Inc. has established a commercial agreement with Scripps Health to expand access to its Nociscan technology for chronic low back pain diagnosis in the San Diego area [1][2][3] - Nociscan utilizes MR Spectroscopy and AI to help physicians identify the sources of chronic low back pain, distinguishing between painful and nonpainful discs [3][5] - The agreement will benefit over 3.2 million people in the greater San Diego Metro area, enhancing the capabilities of leading spine physicians at Scripps Health [1][2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, leveraging biomarkers and proprietary AI algorithms [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively assist physicians in diagnosing disc-related pain [3][5] - The technology processes MRS data from MRI machines to quantify chemical biomarkers associated with disc pain, providing critical insights for treatment optimization [5][6] Industry Context - Chronic low back pain is a significant global healthcare issue, affecting approximately 266 million people worldwide [3] - The partnership with Scripps Health is expected to enhance diagnostic capabilities and treatment strategies for patients suffering from chronic low back pain [2][3]

Core Points - Aclarion, Inc. has announced the adjournment of its Special Meeting of Stockholders originally scheduled for February 28, 2025, to March 5, 2025, to solicit additional votes on proposals outlined in the definitive proxy statement filed with the SEC on February 3, 2025 [2][5][6] - The reconvened Special Meeting will take place at the company's corporate office in Broomfield, Colorado, and stockholders as of the record date of January 6, 2025, are encouraged to vote promptly [3][4] - Proxies submitted for the Special Meeting will remain valid unless revoked, and stockholders can change their votes until March 4, 2025, at 11:59 p.m. Mountain Time [4] Company Overview - Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS) and a proprietary biomarker to enhance clinical treatments for low back and neck pain, addressing a market valued at $134.5 billion in the U.S. [7] - The company is integrating Artificial Intelligence (AI) into its quality control processes to identify poor MRS study data and is exploring AI and machine learning applications to analyze spectroscopy data for better clinical outcome associations [7]

Financial Overview - Full year revenues increased by 4.5%, net income rose by 31.5%, operating income grew by 32.9%, and adjusted EBITDA was up by 9% [7][39] - For Q4 2024, revenues were $74.2 million, up 5.2% from $70.6 million in Q4 2023, with subscription products accounting for 96% of total revenues [25][26] - Adjusted EBITDA for Q4 was $16.2 million, reflecting a 1.3% increase, with an adjusted EBITDA margin of 21.8% [30][39] Business Line Performance - Subscription revenue growth was driven by CredentialStream (28% growth), ShiftWizard (17% growth), and the Competency Suite (8% growth), while legacy products saw declines totaling approximately $1 million [27] - Professional Services revenues increased by 15.7% to $3.1 million [26] Market Data - Remaining performance obligations were $621 million, up from $541 million year-over-year, with expectations of approximately 40% conversion over the next 12 months [27] - The company maintains a strong cash balance of $97.2 million with no long-term debt, positioning it well for potential M&A opportunities [8][22] Company Strategy and Industry Competition - The company declared 2025 as the "Year of the Platform," focusing on enhancing interoperability among its applications and expanding its platform capabilities [11][13] - The HStream platform is expected to drive innovation and efficiency, allowing for faster development of new applications [13][14] Management Commentary on Operating Environment and Future Outlook - Management anticipates organic revenue growth between $302 million and $307 million for 2025, with net income expected between $19.2 million and $21.4 million [8][39] - The company is optimistic about its strong sales pipeline and expects to see growth concentrated in the second half of 2025 [79] Other Important Information - The board approved a dividend increase of 10.7% to $3.1 per share, reflecting confidence in the company's growth strategies [43] - The company has been recognized for its software applications, with the HealthStream Learning Center named the top software in healthcare by G2 [16][18] Q&A Session Summary Question: What will it take to achieve a 7% to 10% growth profile? - Management indicated that achieving this growth would require a combination of organic growth (5% to 7%) and inorganic growth (1% to 3%) through M&A [66][67] Question: Can you quantify the headwinds faced while shifting customers from Perpetual to SaaS? - Management suggested that the headwinds could be similar to the previous year, around 1% to 2% [74] Question: Are you seeing efficiencies from AI in product development? - Management confirmed that they are exploring AI applications internally to improve efficiency, though initial costs may rise before benefits are realized [84][86] Question: How successful have you been in incorporating pricing escalators into new contracts? - Management reported a success rate of over 95% in incorporating escalators into new contracts, which is expected to provide a new base level of growth [92][94] Question: When will the HealthStream Learning Experience (HLX) be fully launched? - The HLX is currently available for sale, with expectations for increased sales in the second half of the year following successful pilot programs [101]

As filed with the Securities and Exchange Commission on December 17, 2024. Registration No. 333-280945 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Wellgistics Health, Inc. (Exact name of registrant as specified in its charter.) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Number) Delaware 8090 93-3264234 (IRS Employer Identification No. ...

Table of Contents As filed with the Securities and Exchange Commission on July 3, 2023 Registration No. 333-______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aclarion, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8071 47-3324725 (I.R.S. Employer Identification Number) 8181 ...